


This article was downloaded by: [Lunds Universitetsbibliotek]

On: 21 November 2008

Access details: Access Details: [subscription number 788833740]

Publisher Informa Healthcare

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Annals of Medicine

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title-content=t71369451>

Can misfolded proteins be beneficial? The HAMLET case

Jenny Pettersson-Kastberg ^a; Sonja Aits ^a; Lotta Gustafsson ^a; Anki Mossberg ^a; Petter Storm ^a; Maria Trulsson ^a; Filip Persson ^a; K. Hun Mok ^{ab}; Catharina Svanborg ^{ac}

^a Department of Microbiology, Immunology and Glycobiology (MIG), Institute of Laboratory Medicine, Lund University, Lund, Sweden ^b Trinity College, School of Biochemistry and Immunology, University of Dublin, Ireland ^c Singapore Immunology Network (SigN), Biomedical Sciences Institutes, Agency for Science, Technology, and Research (A*STAR), Singapore

First Published on: 04 November 2008

To cite this Article Pettersson-Kastberg, Jenny, Aits, Sonja, Gustafsson, Lotta, Mossberg, Anki, Storm, Petter, Trulsson, Maria, Persson, Filip, Hun Mok, K. and Svanborg, Catharina(2008)'Can misfolded proteins be beneficial? The HAMLET case',Annals of Medicine,

To link to this Article: DOI: 10.1080/07853890802502614

URL: <http://dx.doi.org/10.1080/07853890802502614>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

REVIEW ARTICLE

Can misfolded proteins be beneficial? The HAMLET case

JENNY PETTERSSON-KASTBERG¹, SONJA AITS¹, LOTTA GUSTAFSSON¹,
ANKI MOSSBERG¹, PETTER STORM¹, MARIA TRULSSON¹, FILIP PERSSON¹,
K. HUN MOK^{1,2} & CATHARINA SVANBORG^{1,3}

¹Department of Microbiology, Immunology and Glycobiology (MIG), Institute of Laboratory Medicine, Lund University, Lund, Sweden, ²Trinity College, School of Biochemistry and Immunology, University of Dublin, Ireland, and ³Singapore Immunology Network (SIgN), Biomedical Sciences Institutes, Agency for Science, Technology, and Research (A*STAR), Singapore

Abstract

By changing the three-dimensional structure, a protein can attain new functions, distinct from those of the native protein. Amyloid-forming proteins are one example, in which conformational change may lead to fibril formation and, in many cases, neurodegenerative disease. We have proposed that partial unfolding provides a mechanism to generate new and useful functional variants from a given polypeptide chain. Here we present HAMLET (Human Alpha-lactalbumin Made LEthal to Tumor cells) as an example where partial unfolding and the incorporation of cofactor create a complex with new, beneficial properties. Native α -lactalbumin functions as a substrate specifier in lactose synthesis, but when partially unfolded the protein binds oleic acid and forms the tumoricidal HAMLET complex. When the properties of HAMLET were first described they were surprising, as protein folding intermediates and especially amyloid-forming protein intermediates had been regarded as toxic conformations, but since then structural studies have supported functional diversity arising from a change in fold. The properties of HAMLET suggest a mechanism of structure-function variation, which might help the limited number of human protein genes to generate sufficient structural diversity to meet the diverse functional demands of complex organisms.

Key words: *Amyloid, cancer, cell death, HAMLET complex, lactalbumin, oleic acid, prions, protein folding*

Introduction

According to Anfinsen (1), proteins fold to reach the global free energy minimum, where the native three-dimensional structure and its biological function are clearly defined. With the exception of a few metastable native state protein examples (2), recent work on acylphosphatase from *Sulfolobus solfataricus* (3), and HAMLET (4), folding intermediates that possess biological function are rare. Many folding intermediates in their monomeric form exhibit a tendency to aggregate, and some are subsequently converted into protofibrils or amyloid, which, apart from some notable exceptions (5,6), are regarded as potentially toxic conformations. In contrast, the properties of HAMLET (Human Alpha-lactalbumin

Made LEthal to Tumor cells) suggest that folding intermediates can attain functions of physiological importance but completely independent from its originating protein. HAMLET is a complex consisting of partially unfolded α -lactalbumin and oleic acid that kills tumor cells, while leaving healthy, differentiated cells unaffected. This review concerns the structural basis of the tumoricidal activity of HAMLET and of partially unfolded α -lactalbumin. Parallels with amyloid-forming peptides and with other unfolded protein species will also be discussed.

'One gene—one protein—one function'

The paradigm 'one gene, one protein, and one function' was proposed by Tatum and Beadle based

Correspondence: Catharina Svanborg, Department of Microbiology, Immunology and Glycobiology (MIG), Institute of Laboratory Medicine, Lund University, Sölvegatan 23, S-223 62 Lund, Sweden. Fax: +46-46-137468. E-mail: catharina.svanborg@med.lu.se

(Received 11 March 2008; accepted 9 September 2008)

Abbreviations

A β	amyloid- β
ANS	8-anilino-naphthalene-1-sulfonic acid
APP	amyloid precursor protein
C18:1:9 <i>cis</i>	oleic acid
C18:1:11 <i>cis</i>	vaccenic acid
CD	circular dichroism
CIDNP	chemically induced dynamic nuclear polarization
dUTP	2'-deoxyuridine 5'-triphosphate)
EDTA	ethylenediamine tetra-acetic acid
ER	endoplasmic reticulum
ERAD	ER-associated degradation
GAPDH	glyceraldehyde-3-phosphate dehydrogenase
HAMLET	human alpha-lactalbumin made lethal to tumor cells
HDAC	histone deacetylase
HDI	histone deacetylase inhibitors
HeLa cells	Cervical cancer cells from Henrietta Lacks
MAL	multimeric α -lactalbumin
NMR	nuclear magnetic resonance
PBS	Phosphate Buffered Saline
PrP	prion protein
PS	phosphatidyl serine
SDS-PAGE	sodium dodecyl sulfate polyacrylamide gel electrophoresis
TSE	transmissible spongiform encephalopathies
TUNEL	terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling
UPR	unfolded protein response
UV	ultraviolet

on their work on *Neurospora* (bread mold) in the early 1940s, earning them the Nobel Prize in Medicine in 1958 (7). Point mutations were introduced in *Neurospora* strains by X-ray irradiation, and the mutant strains were characterized by their inability to carry out specific biochemical processes. One mutant strain required ρ -aminobenzoic acid for growth, and Tatum and Beadle showed that a single gene discriminated the parent from the mutant and that this gene was essential for the synthesis of ρ -aminobenzoic acid (7). They concluded that a gene encodes a single protein and the 'one gene-one protein-one function paradigm' was born.

More recently, this paradigm has been questioned, especially since the completion of the human genome sequence in 2003. The human genome was shown to contain 30,000–40,000 genes (8,9) coding for 20,000–25,000 proteins (10). This number is inconsistent with function-based estimates, which

Key messages

- HAMLET (human α -lactalbumin made lethal to tumor cells) consists of partially unfolded α -lactalbumin and oleic acid.
- The complex kills tumor cells, while leaving healthy, differentiated cells unaffected.
- The properties of HAMLET suggest that partial unfolding may generate new functional variants from a given polypeptide chain.

propose that protein-dependent functions in the human body would require at least 100,000 proteins (11). Furthermore, there is a remarkably small difference in gene number between species of vastly different complexity. The genome of *Caenorhabditis elegans* contains 20,000 genes (12), which is only five times higher than bacteria like *Pseudomonas aeruginosa* (13). Given the reasonable assumption that biological complexity is reflected in the number of genes, the difference in the number of protein genes is not sufficient to explain the difference in functional complexity between humans, *C. elegans*, and bacteria. Implicit is the need for further structural modifications to distinguish the functional variants.

Thus, even though alternative splicing of mRNA transcripts may generate additional diversity, it is a plausible alternative that polypeptide chains can possess more than one function in some cases. Known structural modifications that allow proteins to change their function include glycosylation, phosphorylation, and oligomerization. Such modifications may occur in response to change of cellular localization, cell type, substrate availability, or ligand binding. Based on the work with HAMLET, we propose that folding intermediates may be functionally distinct from the native, folded species and thus add to the number of functional states attained by a given polypeptide chain (4,14).

HAMLET contains α -lactalbumin—a protein normally involved in lactose synthesis. First the protein is partially unfolded, and then the unfolded protein is bound to oleic acid, which stabilizes its three-dimensional structure. HAMLET is the first example of a protein that in its native state exhibits a well defined function but also acquires a new and beneficial activity after partial unfolding (4,14). More recently, the term 'moonlighting proteins' has been introduced to describe molecules that serve one main and several additional functions, while retaining the same amino acid sequence. As discussed by Jeffery, moonlighting proteins are well

folded (15), but more recently, intrinsically unstructured proteins were proposed to be included in the moonlighting group (16). These proteins lack well defined tertiary structure but can fulfill specific biological functions. HAMLET is distinct from the moonlighting proteins and from the intrinsically unfolded proteins because it undergoes a partial unfolding and remains as such to fulfill its new biological function.

Protein folding

During protein synthesis, the information contained within the mRNA is translated by the ribosome to generate a nascent polypeptide chain, which contains the complete structural information needed to fold to the native state. Many emerging nascent polypeptides are protected from misfolding or aggregation by chaperones (17). The majority of folding occurs in the cytosol, but, for example, secreted proteins are folded by chaperones inside the endoplasmic reticulum (ER) (18). Chaperones may not be essential for protein folding, as a correct protein fold can be obtained *in vitro* in their absence (1), but the protein concentrations and conditions for folding proteins *in vitro* are considerably different from those present within the cell. *In vivo* folding occurs much faster compared to refolding *in vitro*, especially in the case of the formation of disulfide bonds (19). As most of the understanding of protein folding and misfolding is based on *in vitro* systems with highly artificial conditions, there is a need to explore the folding conditions *in vivo*.

It is a great challenge to study protein folding *in vitro* with experimental methods due to conformational exchange in the unstable intermediates. Various biophysical methods such as hydrodynamic measurements, circular dichroism (CD), fluorescence, and nuclear magnetic resonance (NMR) spectroscopy have been applied to yield detailed structural information (20). Another important approach is to study changes in folding upon after substituting individual amino acid residues in a protein (21). In addition, computer simulation techniques have made it possible to perform simulations and to study energy landscapes of individual proteins, including α -lactalbumin (22).

The energy landscape. The number of possible conformations accessible by a polypeptide chain is astronomically large, and yet an unstructured polypeptide can attain to the correct fold in a short period of time (23). This 'Levinthal paradox' has led to the search of folding pathway models. The

'classical view' of protein folding involved linear folding events including the on-pathway, off-pathway, and sequential models (24). In the mid-90s, a 'new view' of protein folding incorporating free energy landscapes was introduced (25). The free energy landscape resembles a U-shaped valley, or 'folding funnel' (26), which is unique for every protein as it is defined by the amino acid sequence. The polypeptide chain is thought to adopt a continuum of folding states on the way down the folding funnel. The free energy is minimized through an increasing number of intra-molecular contacts, and the native fold of a protein is attained when reaching the most thermodynamically stable structure or the global free energy minimum.

The folding process can be more complex if the folding funnel contains various local free energy minima, or kinetic traps (24), and as a result folding intermediates can accumulate. The thermal energy provided within the system is usually sufficient to escape a trap to allow folding to continue down to the lowest free energy state. The properties of the HAMLET complex suggest that the binding of a cofactor may help to stabilize a kinetic trap and keep the protein from reaching the lowest free energy state. The protein thus remains in this energetically unfavorable state by incorporating the fatty acid, and in addition a new biological function is obtained.

Protein misfolding and disease

The term 'misfolding' refers to a change in secondary and/or tertiary structure that abolishes the functional integrity of a native, folded protein. Furthermore, the term infers that misfolding may generate harmful protein species, which damage the cells that produce them. Such variations in the folding of a polypeptide might either lead to disease by gain of toxic activity or by loss of the native biological function (27), potentially leading to disease. About 30% of newly synthesized polypeptides contain errors that prevent folding to the native state, and unless they are removed such misfolded species may cause a transient state of stress due to unfolded protein overload (28). Misfolded protein may also be caused by mutations that permanently hinder the normal folding of the polypeptide chain. In this case, the risk of pathology increases as the unfolded protein accumulates in the tissues, causing aggregation and formation of insoluble fibrils and plaque (11). Native proteins contain varied secondary structural elements such as α -helices and β -sheets, but the misfolded protein aggregates invariably show a preponderance of β -sheet conformation (11,27). The biophysical princi-

ples that rule fibril formation *in vitro* have been extensively studied, and significant inroads have been made into finding therapeutic measures, but much is left to be understood with regards to the *in vivo* conditions (11).

The ER employs two linked mechanisms to deal with misfolded proteins, the unfolded protein response (UPR) and ER-associated degradation (ERAD). The UPR is a stress response, which acts to remodel the ER capacity, while ERAD translocates the misfolded proteins to the cytosol for degradation by the proteasome (18). If these degradation systems fail, due to for example an overload of unfolded or misfolded proteins, the resulting stress response might lead to cell death. Several human diseases are caused by protein misfolding and aggregate formation (27,29). Alzheimer's disease, transmissible spongiform encephalopathies (TSEs), and Parkinson's disease are neurodegenerative disorders included in the conformational diseases (30). In each case, a particular misfolded protein forms amyloid, and amyloid deposits may cause tissue damage. Table I lists the proteins involved in these amyloid diseases so far identified (29). We give further description of amyloid- β and the prion proteins below.

Amyloid- β . Alzheimer's disease is the leading cause of dementia and involves the formation of amyloid plaques in the brain. The amyloid- β (A β) peptide is derived from the amyloid precursor protein (APP) upon cleavage by secretases. APP is a 120-kDa membrane-associated protein, present in both neural and non-neural tissue (31). The plaques consist of A β , a 39–42-residues peptide. The hydrophobic C-terminal domain adopts a β -strand conformation and the N-terminal domain sequence permits the formation of both α -helices and β -sheets (32). Fibril formation is caused by a change in secondary structure to mainly β -sheet (33). Mutations that replace hydrophobic residues in the C-terminal for hydrophilic residues reduce the β -sheet content and decrease the ability to form fibrils (34). After fibrillogenesis, the fibrils eventually aggregate and form plaques, but it is believed that the fibrils themselves are cytotoxic. Geula et al. injected A β fibrils into brains of monkeys and discovered that the fibrils caused neuronal loss (35). The cytotoxic effects were only seen in old monkeys and to a much lower extent in rats, suggesting that this process is stronger in ageing brains in higher-order primates (35). The fibrillogenesis is inhibited in rats by short five-residue peptides, known as β -sheet breakers (36). A combination of the latter two studies is of great interest for the development of

future therapy against Alzheimer's disease.

Prions. The prion proteins (PrPs) cause mammalian spongiform encephalopathies such as Creutzfeldt-Jakob disease in humans and bovine spongiform encephalopathy in cattle (37,38). The prion protein (PrP^c) is a monomeric, non-essential, protease-sensitive glycosylphosphatidylinositol-anchored cell surface protein (37). PrP^c is present in neurons, but the function of the native protein is not fully understood. PrP^c knock-out mice show alterations in, for example, circadian rhythm, brain copper levels, and neural stem cell differentiation. Known PrP^c binding partners include copper, laminin, and laminin receptors (37). PrP^c, which contains 40% α -helices and few β -sheets, can be converted into the cytotoxic form called PrP^{sc} (PrP^{sc}) with 30% α -helical and 45% β -sheet secondary structure (39). PrP^c is monomeric and protease-sensitive, whereas PrP^{sc} is multimeric and more protease-resistant (38). The characteristics of PrP^{sc} as well as its ability to form amyloid fibrils associates TSEs with other conformational diseases (37). The elongation of PrP^{sc} is accomplished by the induction of conformational change of PrP^c by PrP^{sc} to generate more PrP^{sc} and to propagate the disease.

The principal target of prion pathology is the brain, but still most TSEs display prion replication at several extracellular locations. Orally ingested prions are absorbed in the intestines and transported to the blood and lymphoid organs where they replicate. From the spleen, muscles, appendix, or tonsils, the prions are then transported by peripheral nerves to the brain, where they cause pathology with loss of neurons. The cytotoxic process impairs brain function, including memory loss and locomotory problems (40).

Recently, it has been shown that prion replication can occur *in vitro* by cyclic amplification of protein misfolding and that inoculation of *in vitro*-produced prions causes scrapie-like illness (41).

Beneficial prions in yeast. Prion proteins have the unusual capacity to fold into two functionally distinct conformations, one of which is self-perpetuating. These self-replicating protein conformations have been proposed to constitute a kind of molecular memory that transmits genetic information (6) and can cause a switch of state resulting in production of heritable phenotypes (42).

It has also been proposed that the Sup35 protein in *Saccharomyces cerevisiae* can serve as an element of genetic inheritance, propagated in a similar way as hypothesized for the transmission prions in the spongiform encephalopathies. Therefore these

Table I. Human diseases associated with formation of extracellular amyloid deposits or intracellular inclusions with amyloid-like characteristics (29). Reprinted, with permission, from the Annual Review of Biochemistry, Volume 75 ©2006 by Annual Reviews (www.annualreviews.org).

Disease	Aggregating protein or peptide	No. of residues ^a	Native structure of protein or peptide ^b
Neurodegenerative diseases			
Alzheimer's disease ^c	Amyloid- β peptide	40 or 42 ^f	Natively unfolded
Spongiform encephalopathies ^{c,e}	Prion protein or fragments thereof	253	Natively unfolded (residues 1–120) and α -helical (residues 121–230)
Parkinson's disease ^c	α -Synuclein	140	Natively unfolded
Dementia with Lewy bodies ^c	α -Synuclein	140	Natively unfolded
Frontotemporal dementia with Parkinsonism ^c	Tau	352–441 ^f	Natively unfolded
Amyotrophic lateral sclerosis ^c	Superoxide dismutase 1	153	All- β , Ig-like
Huntington's disease ^d	Huntingtin with polyQ expansion	3144 ^g	Largely natively unfolded
Spinocerebellar ataxias ^d	Ataxins with polyQ expansion	816 ^{g,h}	All- β , AXH domain (residues 562–694); the rest are unknown
Spinocerebellar ataxia 17 ^d	TATA box-binding protein with polyQ expansion	339 ^g	$\alpha + \beta$, TBP-like (residues 159–339); unknown (residues 1–158)
Spinal and bulbar muscular atrophy ^d	Androgen receptor with polyQ expansion	919 ^g	All- α , nuclear receptor ligand-binding domain (residues 669–919); rest unknown
Hereditary dentatorubral-pallidoluysian atrophy ^d	Atrophin-1 with polyQ expansion	1185 ^g	Unknown
Familial British dementia ^d	ABri	23	Natively unfolded
Familial Danish dementia ^d	ADan	23	Natively unfolded
Non-neuropathic systemic amyloidoses			
AL amyloidosis ^c	Immunoglobulin light chains or fragments	90 ^f	All- β , Ig-like
AA amyloidosis ^c	Fragments of serum amyloid A protein	76–104 ^f	All- α , unknown fold
Familial Mediterranean fever ^c	Fragments of serum amyloid A protein	76–104 ^f	All- α , unknown fold
Senile systemic amyloidosis ^c	Wild-type transthyretin	127	All- β , prealbumin-like
Familial amyloidotic polyneuropathy ^d	Mutants of transthyretin	127	All- β , prealbumin-like
Hemodialysis-related amyloidosis ^c	β 2-Microglobulin	99	All- β , Ig-like
ApoAI amyloidosis ^d	N-terminal fragments of apolipoprotein AI	80–93 ^f	Natively unfolded
ApoAII amyloidosis ^d	N-terminal fragment of apolipoprotein AII	98 ⁱ	Unknown
ApoAIV amyloidosis ^c	N-terminal fragment of apolipoprotein AIV	70	Unknown
Finnish hereditary amyloidosis ^d	Fragments of gelsolin mutants	71	Natively unfolded
Lysozyme amyloidosis ^d	Mutants of lysozyme	130	$\alpha + \beta$, lysozyme fold
Fibrinogen amyloidosis ^d	Variants of fibrinogen α -chain	27–81 ^f	Unknown
Icelandic hereditary cerebral amyloid angiopathy ^d	Mutant of cystatin C	120	$\alpha + \beta$, cystatin-like
Non-neuropathic localized diseases			
Type II diabetes ^c	Amylin (islet amyloid polypeptide, IAPP)	37	Natively unfolded
Medullary carcinoma of the thyroid ^c	Calcitonin	32	Natively unfolded
Atrial amyloidosis ^c	Atrial natriuretic factor	28	Natively unfolded
Hereditary cerebral hemorrhage with amyloidosis ^d	Mutants of amyloid- β peptide	40 or 42 ^f	Natively unfolded
Pituitary prolactinoma	Prolactin	199	All- α , 4-helical cytokines
Injection-localized amyloidosis ^c	Insulin	21 + 30 ^j	All- α , insulin-like
Aortic medial amyloidosis ^c	Medin	50 ^k	Unknown
Hereditary lattice corneal dystrophy ^d	Mainly C-terminal fragments of kerato-epithelin	50–200 ^f	Unknown
Corneal amyloidosis associated with trichiasis ^c	Lactoferrin	692	$\alpha + \beta$, periplasmic-binding protein-like II
Cataract ^c	γ -Crystallins	Variable	All- β , γ -crystallin-like

Table I (Continued)

Disease	Aggregating protein or peptide	No. of residues ^a	Native structure of protein or peptide ^b
Calcifying epithelial odontogenic tumors ^c	Unknown	46	Unknown
Pulmonary alveolar proteinosis ^d	Lung surfactant protein C	35	Unknown
Inclusion-body myositis ^c	Amyloid- β peptide	40 or 42 ^f	Natively unfolded
Cutaneous lichen amyloidosis ^c	Keratins	Variable	Unknown

^aData refer to number of residues of the processed polypeptide chains that deposit into aggregates.

^bAccording to Structural Classification Of Proteins (SCOP), these are the structural class and fold of the native states of the processed peptides or proteins that deposit into aggregates prior to aggregation.

^cPredominantly sporadic, although in some cases hereditary forms associated with specific mutations are well documented.

^dPredominantly hereditary, although in some cases sporadic forms are documented.

^e5% of the cases are transmitted (e.g. iatrogenic).

^fFragments of various lengths are generated and have been reported to be present in *ex vivo* fibrils.

^gLengths shown refer to the normal sequences with non-pathogenic traits of polyQ.

^hLength shown is for ataxin-1.

ⁱThe pathogenic mutation converts the stop codon into a Gly codon, extending the 77-residue protein by 21 residues.

^jHuman insulin consists of two chains (A and B; 21 and 30 residues) covalently linked by disulfide bridges.

^kMedin is the 245–294 fragment of human lactadherin.

protein factors have been called yeast prions (43). It has been suggested that the Sup35p protein in yeast may adopt a specific self-propagating conformation, similar to mammalian prions, giving rise to the [psi+] nonsense suppressor determinant, inherited in a non-Mendelian fashion. Sup35 molecules interact with each other through their N-terminal domains in [psi+], but not [psi-] cells. This interaction is critical for [psi+] propagation, since its disruption leads to a loss of [psi+]. Sup35p forms high molecular weight aggregates in [psi+] cells, which inhibit Sup35p activity leading to a [psi+] non-sense-suppressor phenotype (44). This self-perpetuating change in Sup35p conformation shows that deliberate genetic engineering can create new elements of genetic inheritance (43). In addition to Sup35, there are several fungal prions known. Recently, CPEB (cytoplasmic polyadenylation element-binding protein) was shown to regulate mRNA translation through an N-terminal extension that changes conformation when fused to a reporter protein in yeast (42).

HAMLET—A tumoricidal complex of partially unfolded α -lactalbumin and oleic acid

HAMLET is a complex of partially unfolded α -lactalbumin and oleic acid (C18:1:9*cis*) (4) that kills tumor cells and immature cells but not the healthy differentiated cells so far tested. The tumoricidal activity was discovered in casein, obtained after low pH precipitation of human milk (14). To identify the active component, casein was fractionated by ion exchange chromatography. The active complex showed high affinity for the matrix and was only eluted after high salt. The major component of the

eluate was α -lactalbumin, and the fraction was named MAL (multimeric α -lactalbumin) due to the oligomeric nature on SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) (14,45).

Native α -lactalbumin was shown to lack tumoricidal activity, suggesting that MAL might be structurally modified. As no posttranslational modifications were detected, we examined the conformation of α -lactalbumin in the complex, using CD spectroscopy and the fluorescent hydrophobic dye ANS (8-anilinonaphthalene-1-sulfonic acid). MAL contained partially unfolded protein, as expected from the low pH that was used to precipitate MAL from milk. In addition, the active complex contained a cofactor, which defined the activity and prevented α -lactalbumin from reverting to the native state. The cofactor was identified as oleic acid, and the conditions required for complex formation were defined by deliberate conversion of native α -lactalbumin to HAMLET in the presence of oleic acid (4).

Molecular properties

The identity of α -lactalbumin has been known since the late 19th century (48). The 14-kDa protein consists of 123 amino acids and is produced in great amounts in human breast-milk (49,50). The first crystals were not obtained until about 64 years later (51), but since then many groups have determined the structure of native human α -lactalbumin (52–54) with similar results. The crystal structure reveals two domains, the α - and the β -domain (52). The large α -helical domain contains three major α -helices (amino acids 5–11, 23–34, 86–98) and two short 3_{10} -helices (amino acids 18–20, 115–118) (Figure 1). The small β -domain consists of a triple-stranded




Figure 1. Schematic of HAMLET formation from α -lactalbumin and oleic acid. Partial unfolding is achieved by removal of calcium, and the unfolded protein binds oleic acid. Structures from pdbID 1HML (104) and 1LFO (105) were modified in MOLMOL (106).

antiparallel β -sheet (amino acids 40–50) and a short 3_{10} -helix (amino acids 76–82) (52). The protein is stabilized by four disulfide bonds (55) and a high-affinity calcium binding site (56). The disulfide bonds are spread throughout the protein (C6–120, C28–111, C61–77, C73–91) and connect the two domains.

In addition to X-ray crystallographic studies of the native state, α -lactalbumin has been important as a model of protein folding (57–59). The protein forms a molten globule (57), which is a partially unfolded state characterized by a native-like secondary structure with a loss of well defined tertiary packing (46,47). The α -lactalbumin molten globule has been studied by several techniques including hydrogen exchange combined with NMR (60,61), photochemically induced dynamic nuclear polarization (CIDNP) NMR (58), limited proteolysis (62), and mutational studies (63). The results indicate that the α -lactalbumin molten globule is characterized by a native-like, structured α -domain and a less ordered β -domain, and the α -domain has been shown to be stabilized by a hydrophobic core (64).

HAMLET is formed from α -lactalbumin and oleic acid in a two-step procedure (Figure 1). First, the protein is partially unfolded by removal of calcium, which results in a conformational change to the apo state. Unfolding increases the affinity for oleic acid and enables the fatty acid to form a complex with the protein. The HAMLET structure has been examined by CD, fluorescence, and NMR spectroscopy (4). By near-ultraviolet (UV) CD spectroscopy HAMLET CD spectrum resembled apo α -lactalbumin but with a decrease in signal suggesting a partially unfolded state (4). Increased exposure of hydrophobic domains was detected using the fluorescent hydrophobic dye ANS. The HAMLET ANS spectrum showed a blue shift compared to the native protein indicating exposure of hydrophobic surfaces enabling ANS to bind. The $^1\text{H-NMR}$ spectrum of HAMLET showed broader peaks indicating a less-ordered protein, confirming

the near-UV CD result. Oleic acid was detected in the spectrum, and the signal was broader than oleic acid alone, suggesting that oleic acid was integrated in the protein (4). The techniques suggested that apo α -lactalbumin is in a molten globule state (46,47) in the HAMLET complex (discussed below).

Sequence variation in α -lactalbumins

α -Lactalbumins are structurally conserved among species, suggesting that α -lactalbumin sequence variation among species might be used as a tool to understand the molecular basis of HAMLET formation and function (65). We have explored the sequence variation in naturally occurring α -lactalbumins from different species to understand the contribution of different regions of the molecule to the formation of HAMLET-like complexes with oleic acid. Human, bovine, equine, caprine, and porcine α -lactalbumin show a 71% sequence homology. The calcium-binding site is 100% conserved, but sequence differences are spread through the protein.

α -Lactalbumins were purified from human, bovine, equine, caprine, and porcine milk, and each protein was treated with EDTA (ethylenediamine tetra-acetic acid) and subjected to conversion on an oleic acid-conditioned column, according to the HAMLET conversion protocol. Each of the proteins was retained on the oleic acid-conditioned column and eluted with high salt as a HAMLET-like complexes. The human protein showed a higher yield (62%) than the other species (24%–46%). The near-UV CD spectra of native human, bovine, and caprine α -lactalbumin resembled previous results (62,66–71) with equine α -lactalbumin being the least folded protein while the porcine protein was slightly more folded. All the HAMLET-like complexes had lost tertiary structure and near-UV CD signals compared to the native protein. The tumoricidal activity of the HAMLET-like complexes was

tested on lymphoma cells, and viability was determined by trypan blue exclusion: all complexes were shown to be tumoricidal, with similar activity as HAMLET, suggesting that sequence variation does not change the ability of α -lactalbumins to form active HAMLET complexes. Tumor cell viability was not affected when applying fresh milk at high concentrations, consistent with α -lactalbumin being native and oleic acid-bound in milk triglycerides (72).

Lipids as cofactors in HAMLET

Partially unfolded α -lactalbumin alone does not kill the tumor cells, suggesting that oleic acid is crucial for tumoricidal activity interacts specifically with longchained unsaturated fatty acids (70). We determined the ability of different fatty acids to form HAMLET-like complexes with apo α -lactalbumin and the tumoricidal activity of those complexes, using fatty acids differing in carbon chain length, saturation, and double bond conformation. The C18 *cis* fatty acids and other fatty acids with *cis* double bonds readily formed complexes with apo α -lactalbumin on the ion exchange matrix. The highest yield was obtained for oleic acid (C18:1:9*cis*) and vaccenic acid (C18:1:11*cis*) (73). In addition, complex formation with partially unfolded α -lactalbumin was achieved with palmitic acid (C16, *cis*) and arachidonic acid (C20, *cis*). In contrast, fatty acids of similar carbon chain length but with the double bond in the *trans* orientation were unable to form complexes, as were saturated fatty acids.

The tumoricidal activity of the different fatty acid complexes was tested on mouse leukemia cells, as the loss of cell viability and DNA fragmentation. Human α -lactalbumin in complex with C18:1:9*cis* (HAMLET) and C18:1:11*cis* killed the cells efficiently and caused DNA fragmentation, but complexes with palmitic acid (C16, *cis*) and arachidonic acid (C20, *cis*) were less tumoricidal.

Calcium-free and unfolded α -lactalbumin kills tumor cells in complex with oleic acid

α -Lactalbumin unfolds when the protein is exposed to conditions that remove the strongly bound calcium ion, such as treatment with EDTA (74). Unfolding with EDTA is reversible, however, as α -lactalbumin reverts to the native state if calcium is present. By mutating the calcium-binding site, both calcium binding and reversion may be prevented (70). The D87 mutant cannot bind calcium and thus remains partially unfolded in the presence of calcium and at natural solvent conditions. We

showed that the D87 mutant forms a tumoricidal complex with oleic acid. The results suggested that the native fold is not required for the formation of the tumoricidal complex or for the tumoricidal activity. Furthermore, they excluded that calcium in α -lactalbumin is involved in the tumoricidal effect of the complex.

Mechanisms of cell death in response to HAMLET

Apoptosis and autophagy in response to HAMLET

More than 40 different tumor cell lines have been exposed to HAMLET *in vitro*, and all were sensitive, regardless of tumor type, species, and tissue origin (75). The HAMLET-treated cells showed characteristics of apoptosis (14), and HAMLET caused mitochondrial swelling and loss of mitochondrial membrane potential (76,77) accompanied by cytochrome C release, caspase activation (77), and phosphatidyl serine (PS) exposure on the cell surface. Apoptosis was not the cause of tumor cell death, however, as caspase inhibitors did not inhibit the death response (76–78). HAMLET was shown to kill tumor cells regardless of their Bcl-2 and *p53* status (78), further illustrating how death in response to HAMLET differs from classical apoptosis.

In parallel with apoptosis, HAMLET triggers macroautophagy (Aits S, Gustafsson L, Hallgren O, Brest P, Gustafsson M, Trulsson M, et al., in press, Int J of Cancer, 2008). Macroautophagy occurs at basal levels in most cells but increases in response to cellular stress such as starvation (79), and extreme responses have been proposed as a form of programmed cell death, called autophagic/type II cell death (80,81). After HAMLET treatment, double-membrane-enclosed vesicles, LC3 translocation and accumulation, typical of macroautophagy, were observed in tumor cells. Furthermore, inhibition of macroautophagy by Beclin-1 and Atg5 siRNAs significantly reduced HAMLET-induced cell death, consistent with the involvement of Beclin-1, LC3, and Atg5 in autophagosome formation, suggesting that autophagy is one aspect of cell death in response to HAMLET.

ER stress and proteasome response to HAMLET

HAMLET binds to the surface of tumor cells and enters the cytoplasm (4,82–84), but native α -lactalbumin, is only taken up in small amounts (4,45,83), suggesting that unfolding of α -lactalbumin and fatty acid binding are both required for uptake into tumor cells. We have hypothesized that the internalization of

HAMLET may trigger the ER and proteasome responses normally activated by endogenous, unfolded proteins. Furthermore, 20S proteasomes have been proposed to degrade unfolded α -lactalbumin *in vitro* (85). Preliminary results suggested that the recognition of unfolded α -lactalbumin by the ER and by 20S proteasomes and the subsequent failure of these responses to scavenge and degrade α -lactalbumin are essential to trigger tumor cell death.

Nuclear receptors and chromatin interactions of HAMLET

HAMLET accumulates in the nuclei of tumor cells, and histones have been identified as nuclear receptors for HAMLET (82). By confocal microscopy, histones and HAMLET have been shown to colocalize in the nuclei of tumor cells. High-affinity interactions with histones have been documented with isolated histones, and in nuclear extracts HAMLET, histones, and DNA form virtually insoluble complexes. Healthy cells only take up small amounts of HAMLET, and there is no evidence of nuclear translocation of HAMLET in healthy cells (82,83).

The chromatin accessibility is controlled by acetylation and deacetylation of the histone tail. Histone deacetylases (HDACs), which close the chromatin, are often overexpressed in tumor cells, and HDAC inhibitors (HDIs) are therefore used to open up the chromatin to tumoricidal agents. Recently, we have shown that HAMLET acts in synergy with HDIs, by enhancing the hyperacetylation response to the HDIs and by promoting cell death (86). We also showed that HAMLET binds to tailless histone proteins, in contrast to HDIs, which modify the histone tail. Future studies in tumor models should investigate if the combination of HAMLET and HDIs may be used to increase the therapeutic effect.

HAMLET and cancer therapy

Cancer therapeutics often lack tumor selectivity and cause severe side effects due to tissue toxicity. There is a need to identify new drugs that selectively kill tumor cells, and significant progress is being made in this area. Examples of new, targeted therapies are growth factor inhibitors, blockers of angiogenesis, and proapoptotic drugs. HAMLET is an interesting candidate drug, as the complex shows a high degree of selectivity for tumor cells *in vitro* and *in vivo*. The tumoricidal effect of HAMLET *in vivo* has been tested both in animals and in patients (83,87,88).

Human glioblastoma xenografts

A rat glioblastoma model, which reproduces the invasive growth of the human tumors, was used to test the therapeutic effect of HAMLET (83). Nude rats were xenotransplanted with glioblastoma cells obtained from surgical specimens of human tumors that were injected into the striatum. The tumor area was subsequently infused with HAMLET or α -lactalbumin by intracerebral convection-enhanced delivery, and the tumor size was followed by magnetic resonance imaging. HAMLET was shown to reduce the tumor size and to delay the development of pressure-related symptoms. HAMLET caused apoptosis in the tumor, as determined by TUNEL (terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling)-staining on biopsies, but there was no apoptotic response to α -lactalbumin. No toxic side effects were observed.

Placebo-controlled study of human skin papillomas

The effect of HAMLET was further studied in patients with skin papillomas (87). Patients with severe, therapy-resistant papillomas on hands and feet were enrolled in a placebo-controlled and double-blind study. HAMLET or saline solution was applied daily for 3 weeks, and the effect on lesion volume was recorded. This phase was followed by an open 3-week trial where all the patients received HAMLET. Finally, most of the patients were examined 2 years after the end of the study. All the HAMLET-treated patients showed a decrease in lesion volume by at least 75%, and after 2 years all lesions had resolved in 83% of the patients. We concluded that HAMLET had beneficial effects on skin papillomas without side effects.

Human bladder cancer

The papilloma study suggested that topical HAMLET administration might be useful also in cancer patients. We selected to study bladder cancer, as a variant of topical treatments are used for intravesical instillation to prevent or delay cystectomy (88). The response to HAMLET in bladder cancer patients was studied after intravesical application in nine patients, who received five daily HAMLET instillations prior to scheduled surgery. HAMLET caused a rapid increase in cell shedding. The shed cells showed signs of apoptosis but NaCl, phosphate buffered saline (PBS), and α -lactalbumin did not trigger cell shedding. At surgery, a reduction in tumor size was observed in eight of nine patients, and four of the patients had positive TUNEL-staining in biopsies from the remaining tumor,




Figure 2. Summary of the structural properties of HAMLET and the basis of the tumoricidal activity.




Figure 3. Summary of known cellular targets involved in HAMLET-induced tumor cell death.

showing that HAMLET has a direct effect on bladder cancer tissue, *in vivo* (88).

Parallels between HAMLET, prions, and amyloid

Fibril formation

Amyloid fibrils are composed of β -strands arranged into β -sheets in which the strands are hydrogen-bonded 4.7 Å apart. In an antiparallel arrangement the repeat distance is 9.6 Å, and diffraction patterns from highly oriented amyloid fibril samples show layer lines at 9.6 Å (89). To examine if HAMLET might behave in a similar manner, solutions were left at various temperatures and times (days to months), and the presence of aggregates was examined by electron and atomic force microscopy. No fibril formation was detected with either of the techniques. By electron and atomic force microscopy HAMLET was shown to be mainly monomeric (unpublished data, Pettersson-Kastberg J, Malisauskas M, Morozova-Roche L, Svanborg C, 2007). Solution NMR studies also indicate that the partially folded protein-oleic acid complex is monomeric (unpublished data, Mok KH, 2008). The monomeric state in solution does not exclude the possibility that multimers might be formed upon contact with cell membranes.

Fibrillogenesis has been proposed to be a membrane-associated process (90–93). Fibril formation of several proteins, including lysozyme, cytochrome C, histone H1, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), transthyretin, endostatin, and α -lactalbumin, was enhanced by membranes containing PS, and fluorescent lipid tracers indicated the presence of lipid in these amyloid fibrils (92,93). The rapid fibril formation might reflect the low pH at the membrane surface (93) or the high proportion of hydrogen bonds in the amyloidogenic proteins that are incompletely formed (90). Endostatin, a tumor angiogenesis inhibitor, was shown only to form fibrils on acidic PS membranes (92), and since cancer cells have been reported to expose PS on the surface (94), they might be a target for endostatin, which increases membrane permeability (91,92).

It is also possible that the fibrillar constituents may form complexes with membrane lipids and gain access to cells in a manner similar to HAMLET. The properties of membrane-associated HAMLET remain to be defined. Whether the effects of the fatty acids on the partially folded α -lactalbumin protein are equivalent to the membrane bilayer interactions of membrane proteins remains unknown. Our studies show that the partial unfolding of the protein

must precede the contact with fatty acids, suggesting that the mode of interaction is not exclusively fatty acid-induced.

Are cofactors involved in amyloid fibril formation and disease pathogenesis?

Based on the HAMLET complex, we have proposed that cofactors may be needed to define new, bioactive folding variants. The availability of cofactors in certain tissues might also help ensure that active complexes are formed only at the site where the new function is beneficial. As unfolding may occur quite frequently (29), an elegant solution would be to recruit cofactors available within specific tissue environments to prevent unfolded protein molecules from becoming cytotoxic.

The need for tissue cofactors in amyloid and prion formation and toxicity has been extensively discussed. Prion aggregates contain different prion protein species varying from non-fibrillar oligomers to large amyloid plaques (37). These different molecular forms have been produced *in vitro* but have mostly not been toxic, and thus the molecular basis of toxicity is not fully understood. The aggregates are formed by the specific misfolded protein species, but other components, including other proteins or carbohydrates, may be incorporated (95).

While it is accepted that the change in fold is required for disease, the possible involvement of other additional proteins or nucleic acids is still being discussed (37,38,96). Three different classes of possible cofactors have been suggested (96). The first includes cellular receptors, which might facilitate conversion of PrP^c to PrP^{sc} and the uptake by endosomes. The known interactions with, for example, the laminin receptor and heparan sulfate support this hypothesis. A second possibility involves nucleic acids. The prion protein is known to bind to nucleic acids, and the binding results in a structural modification. The third possibility includes lipids, which could act as chaperones. This theory is supported by the fact that different lipids can stabilize α -helix- and β -sheet-enriched structures (96). It may be speculated that similar interactions guide the way in which oleic acid stabilizes the partially unfolded state of α -lactalbumin, which contains both α -helical and β -sheet structure, and the prion proteins.

Amyloid cytotoxicity

It is not clear how prions and amyloid fibers exert their cytotoxic effects. It is well known, for example,

that aggregated A β fibrils kill healthy neuronal cells (35), but on the other hand there is increasing evidence that folding intermediates (protofibrils) can be toxic. Silveira et al. have identified aggregates with 14–28 PrP molecules as the most efficient disease inducers, but neither the small oligomers nor the larger aggregates are toxic (97). The lysozyme amyloids were proposed to be cytotoxic as the oligomers killed neuroblastoma cells by an apoptosis-like mechanism and the fibrils lead to a necrosis-like death (98). In this case, the amyloid was obtained after 12 days at pH 2.2 and 57°C. Bovine α -lactalbumin forms fibrils at pH 2.0 and 37°C (99). The same results were obtained with *S*-(carboxymethyl)- α -lactalbumin, a variant with three out of four disulfide bridges reduced. Yang et al. obtained bovine α -lactalbumin fibril formation from pH 4.5 and below. The fibrillogenesis was completely inhibited by oleic acid (640 μ M) at pH 4.0–4.5, and insoluble aggregates were obtained (100). This did not occur at lower pH, and at neutral pH the apo protein did not form fibrils. However, GAPDH fibrils, formed under oxidizing conditions, kill cervical cancer cells (HeLa) cells by apoptosis, but the effect on healthy cells is not known. In contrast to HAMLET, both fibrils and amyloid have been shown to kill healthy cells (35).

Recently, an antimicrobial peptide of bacterial origin (plantaricin A) was shown to form protein-lipid amyloid-like fibrils upon binding to negatively charged phospholipid-containing membranes. This resulted in killing of bacteria and leukemic T-cells and suggested a possible mechanistic connection between fibril formation and the cytotoxicity of plantaricin A (101). It is not clear if this mechanism is related to the antimicrobial activity of HAMLET (102), but it is important to keep in mind that HAMLET selectively kills tumor cells by apoptosis, and not by necrosis, as for example plantaricin A.

Summary

With the exception of a few metastable native state proteins, folding intermediates that possess biological function are rare. We have reviewed this question, using amyloid, prions, HAMLET, and antibacterial peptides as examples. The tumoricidal effect of HAMLET requires unfolding of α -lactalbumin and binding of oleic acid. A summary of the structural properties of HAMLET and the basis of the tumoricidal activity is shown in Figure 2. In HAMLET, α -lactalbumin resembles a molten globule, as the secondary structure of α -lactalbumin is retained but the molecule lacks tertiary packing. The

fatty acid interaction shows specificity, as only oleic acid-like fatty acids form active complexes with apo α -lactalbumin. The protein component can be more varied, however, as α -lactalbumin species variants form tumoricidal complexes with oleic acid (70).

The multi-faceted cell death response to HAMLET is illustrated in Figure 3. We have used the 'hydra' metaphor to illustrate that HAMLET acts on different cell organelles, potentially triggering many different cell death pathways (103). The results suggest that the complex cellular response is advantageous, as it ensures that HAMLET may kill a broad spectrum of tumor cells, despite their resistance to programmed cell death.

Acknowledgements

The studies summarized here were performed over several years and were supported by the Sharon D. Lund foundation grant and the American Cancer Society, the Swedish Cancer Society, the Swedish Pediatric Cancer Foundation, the Medical Faculty (Lund University), the S—derberg Foundation, the Segerfalk Foundation, the French Medical Research Foundation (FRM, Paris), the Anna-Lisa and Sven-Erik Lundgren Foundation for Medical Research, the Knut Alice Wallenberg Foundation, the Lund City Jubileumsfond, the John and Augusta Persson Foundation for Medical Research, the Maggie Stephens Foundation, the Gunnar Nilsson Cancer Foundation, the Inga-Britt och Arne Lundberg foundation, the HJ Forssman Foundation for Medical Research and the Royal Physiographic Society.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. Catharina Svanborg is a shareholder in NatImmune, which has been involved in HAMLET drug development. There has been no interaction with the company or support received for the studies described here.

References

1. Anfinsen CB. Principles that govern the folding of protein chains. *Science*. 1973;181:223–30.
2. Cabrita LD, Bottomley SP. How do proteins avoid becoming too stable? Biophysical studies into metastable proteins. *Eur Biophys J*. 2004;33:83–8.
3. Bemporad F, Gsponer J, Hopearuoho HI, Plakoutis G, Stati G, Stefani M, et al. Biological function in a non-native partially folded state of a protein. *EMBO J*. 2008;27:1525–35.
4. Svensson M, Hakansson A, Mossberg AK, Linse S, Svanborg C. Conversion of α -lactalbumin to a protein inducing apoptosis. *Proc Natl Acad Sci U S A*. 2000;97:4221–6.

5. Fowler DM, Koulov AV, Alory-Jost C, Marks MS, Balch WE, Kelly JW. Functional amyloid formation within mammalian tissue. *PLoS Biol.* 2006;4:e6.
6. Shorter J, Lindquist S. Prions as adaptive conduits of memory and inheritance. *Nat Rev Genet.* 2005;6:435–50.
7. Beadle GW, Tatum EL. Genetic control of biochemical reactions in neurospora. *Proc Natl Acad Sci U S A.* 1941; 27:499–506.
8. Green ED, Chakravarti A. The human genome sequence expedition: views from the ‘base camp’. *Genome Res.* 2001;11:645–51.
9. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. *Science.* 2001;291:1304–51.
10. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. *Nature.* 2004;431:931–45.
11. Dobson CM. Protein misfolding, evolution and disease. *Trends Biochem Sci.* 1999;24:329–32.
12. Claverie JM. Gene number. What if there are only 30,000 human genes? *Science.* 2001;291:1255–7.
13. Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrenner P, Hickey MJ, et al. Complete genome sequence of *Pseudomonas aeruginosa* PA01, an opportunistic pathogen. *Nature.* 2000;406:959–64.
14. Hakansson A, Zhivotovsky B, Orrenius S, Sabharwal H, Svanborg C. Apoptosis induced by a human milk protein. *Proc Natl Acad Sci U S A.* 1995;92:8064–8.
15. Jeffery CJ. Moonlighting proteins. *Trends Biochem Sci.* 1999;24:8–11.
16. Tompa P, Szasz C, Buday L. Structural disorder throws new light on moonlighting. *Trends Biochem Sci.* 2005;30:484–9.
17. Hartl FU, Hayer-Hartl M. Molecular chaperones in the cytosol: from nascent chain to folded protein. *Science.* 2002;295:1852–8.
18. Bukau B, Weissman J, Horwich A. Molecular chaperones and protein quality control. *Cell.* 2006;125:443–51.
19. Gething MJ, Sambrook J. Protein folding in the cell. *Nature.* 1992;355:33–45.
20. Mok KH, Hore PJ. Photo-CIDNP NMR methods for studying protein folding. *Methods.* 2004;34:75–87.
21. Dobson CM. The structural basis of protein folding and its links with human disease. *Philos Trans R Soc Lond B Biol Sci.* 2001;356:133–45.
22. Vendruscolo M, Paci E, Karplus M, Dobson CM. Structures and relative free energies of partially folded states of proteins. *Proc Natl Acad Sci U S A.* 2003;100:14817–21.
23. Levinthal C. Are there pathways for protein folding? *J Chim Phys.* 1968;65:44–5.
24. Dill KA, Chan HS. From Levinthal to pathways to funnels. *Nat Struct Biol.* 1997;4:10–9.
25. Baldwin RL. The nature of protein folding pathways: the classical versus the new view. *J Biomol NMR.* 1995;5:103–9.
26. Bryngelson JD, Onuchic JN, Succi ND, Wolynes PG. Funnels, pathways, and the energy landscape of protein folding: a synthesis. *Proteins.* 1995;21:167–95.
27. Soto C. Protein misfolding and disease; protein refolding and therapy. *FEBS Lett.* 2001;498:204–7.
28. Kaufman RJ, Scheuner D, Schroder M, Shen X, Lee K, Liu CY, et al. The unfolded protein response in nutrient sensing and differentiation. *Nat Rev Mol Cell Biol.* 2002;3:411–21.
29. Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. *Annu Rev Biochem.* 2006;75:333–66.
30. Trzesniewska K, Brzyska M, Elbaum D. Neurodegenerative aspects of protein aggregation. *Acta Neurobiol Exp (Wars).* 2004;64:41–52.
31. Selkoe DJ, Podlisny MB, Joachim CL, Vickers EA, Lee G, Fritz LC, et al. Beta-amyloid precursor protein of Alzheimer disease occurs as 110- to 135-kilodalton membrane-associated proteins in neural and nonneural tissues. *Proc Natl Acad Sci U S A.* 1988;85:7341–5.
32. Soto C, Castano EM, Frangione B, Inestrosa NC. The α -helical to β -strand transition in the amino-terminal fragment of the amyloid β -peptide modulates amyloid formation. *J Biol Chem.* 1995;270:3063–7.
33. Barrow CJ, Yasuda A, Kenny PT, Zagorski MG. Solution conformations and aggregational properties of synthetic amyloid β -peptides of Alzheimer’s disease. Analysis of circular dichroism spectra. *J Mol Biol.* 1992;225:1075–93.
34. Hilbich C, Kisters-Woike B, Reed J, Masters CL, Beyreuther K. Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer’s disease beta A4 peptides. *J Mol Biol.* 1992;228:460–73.
35. Geula C, Wu CK, Saroff D, Lorenzo A, Yuan M, Yankner BA. Aging renders the brain vulnerable to amyloid β -protein neurotoxicity. *Nat Med.* 1998;4:827–31.
36. Soto C, Sigurdsson EM, Morelli L, Kumar RA, Castano EM, Frangione B. β -sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer’s therapy. *Nat Med.* 1998;4:822–6.
37. Caughey B, Baron GS. Prions and their partners in crime. *Nature.* 2006;443:803–10.
38. Prusiner SB, Scott MR, DeArmond SJ, Cohen FE. Prion protein biology. *Cell.* 1998 1;93:337–48.
39. Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D, et al. Conversion of α -helices into β -sheets features in the formation of the scrapie prion proteins. *Proc Natl Acad Sci U S A.* 1993;90:10962–6.
40. Aguzzi A, Heikenwalder M. Pathogenesis of prion diseases: current status and future outlook. *Nat Rev Microbiol.* 2006;4:765–75.
41. Castilla J, Saa P, Hetz C, Soto C. In vitro generation of infectious scrapie prions. *Cell.* 2005;121:195–206.
42. Si K, Lindquist S, Kandel ER. A neuronal isoform of the aplysia CPEB has prion-like properties. *Cell.* 2003;115: 879–91.
43. Lindquist S, Krobitsch S, Li L, Sondheimer N. Investigating protein conformation-based inheritance and disease in yeast. *Philos Trans R Soc Lond B Biol Sci.* 2001;356:169–76.
44. Paushkin SV, Kushnirov VV, Smirnov VN, Ter-Avanesyan MD. Propagation of the yeast prion-like [psi+] determinant is mediated by oligomerization of the SUP35-encoded polypeptide chain release factor. *EMBO J.* 1996;15:3127–34.
45. Svensson M, Sabharwal H, Hakansson A, Mossberg AK, Lipniunas P, Leffler H, et al. Molecular characterization of α -lactalbumin folding variants that induce apoptosis in tumor cells. *J Biol Chem.* 1999;274:6388–96.
46. Arai M, Kuwajima K. Role of the molten globule state in protein folding. *Adv Protein Chem.* 2000;53:209–82.
47. Ptitsyn OB. Molten globule and protein folding. *Adv Protein Chem.* 1995;47:83–229.
48. Halliburton WD. The proteids of milk. *J Physiol.* 1890; 11:448–63.
49. Heine WE, Klein PD, Reeds PJ. The importance of α -lactalbumin in infant nutrition. *J Nutr.* 1991;121:277–83.
50. Lonnerdal B, Forsum E. Casein content of human milk. *Am J Clin Nutr.* 1985;41:113–20.
51. Zweig G, Block RJ. Studies on bovine whey proteins. III. The preparation of crystalline α -lactalbumin and β -lactoglobulin ferrilactin. *Arch Biochem Biophys.* 1954;51:200–7.

52. Acharya KR, Ren JS, Stuart DI, Phillips DC, Fenna RE. Crystal structure of human α -lactalbumin at 1.7 Å resolution. *J Mol Biol.* 1991;221:571–81.
53. Chandra N, Brew K, Acharya KR. Structural evidence for the presence of a secondary calcium binding site in human α -lactalbumin. *Biochemistry.* 1998;37:4767–72.
54. Fenna RE. Crystallization of human α -lactalbumin. *J Mol Biol.* 1982;161:211–5.
55. Vanaman TC, Brew K, Hill RL. The disulfide bonds of bovine α -lactalbumin. *J Biol Chem.* 1970;245:4583–90.
56. Hiraoka Y, Segawa T, Kuwajima K, Sugai S, Murai N. α -Lactalbumin: a calcium metalloprotein. *Biochem Biophys Res Commun.* 1980;95:1098–104.
57. Kuwajima K. The molten globule state of α -lactalbumin. *FASEB J.* 1996;10:102–9.
58. Mok KH, Nagashima T, Day IJ, Hore PJ, Dobson CM. Multiple subsets of side-chain packing in partially folded states of α -lactalbumins. *Proc Natl Acad Sci U S A.* 2005;102:8899–904.
59. Peng ZY, Kim PS. A protein dissection study of a molten globule. *Biochemistry.* 1994;33:2136–41.
60. Schulman BA, Redfield C, Peng ZY, Dobson CM, Kim PS. Different subdomains are most protected from hydrogen exchange in the molten globule and native states of human α -lactalbumin. *J Mol Biol.* 1995;253:651–7.
61. Chyan CL, Wormald C, Dobson CM, Evans PA, Baum J. Structure and stability of the molten globule state of guinea-pig α -lactalbumin: a hydrogen exchange study. *Biochemistry.* 1993;32:5681–91.
62. Polverino de Laureto P, Frare E, Gottardo R, Fontana A. Molten globule of bovine α -lactalbumin at neutral pH induced by heat, trifluoroethanol, and oleic acid: a comparative analysis by circular dichroism spectroscopy and limited proteolysis. *Proteins.* 2002;49:385–97.
63. Wu LC, Peng ZY, Kim PS. Bipartite structure of the α -lactalbumin molten globule. *Nat Struct Biol.* 1995;2:281–6.
64. Wu LC, Kim PS. A specific hydrophobic core in the alpha-lactalbumin molten globule. *J Mol Biol.* 1998;280:175–82.
65. Pettersson J, Mossberg AK, Svanborg C. α -Lactalbumin species variation, HAMLET formation, and tumor cell death. *Biochem Biophys Res Commun.* 2006;345:260–70.
66. Chedad A, Van Dael H. Kinetics of folding and unfolding of goat α -lactalbumin. *Proteins.* 2004;57:345–56.
67. Dolgikh DA, Gilmanshin RI, Brazhnikov EV, Bychkova VE, Semisotnov GV, Venyaminov S, et al. α -Lactalbumin: compact state with fluctuating tertiary structure? *FEBS Lett.* 1981;136:311–5.
68. Peng ZY, Wu LC, Schulman BA, Kim PS. Does the molten globule have a native-like tertiary fold? *Philos Trans R Soc Lond B Biol Sci.* 1995;348:43–7.
69. Permyakov SE, Uversky VN, Veprintsev DB, Cherskaya AM, Brooks CL, Permyakov EA, et al. Mutating aspartate in the calcium-binding site of α -lactalbumin: effects on the protein stability and cation binding. *Protein Eng.* 2001;14:785–9.
70. Svensson M, Fast J, Mossberg AK, Durringer C, Gustafsson L, Hallgren O, et al. α -Lactalbumin unfolding is not sufficient to cause apoptosis, but is required for the conversion to HAMLET (human α -lactalbumin made lethal to tumor cells). *Protein Sci.* 2003;12:2794–804.
71. Wu LC, Schulman BA, Peng ZY, Kim PS. Disulfide determinants of calcium-induced packing in α -lactalbumin. *Biochemistry.* 1996;35:859–63.
72. Jensen RG. The lipids in human milk. *Prog Lipid Res.* 1996;35:53–92.
73. Svensson M, Mossberg AK, Pettersson J, Linse S, Svanborg C. Lipids as cofactors in protein folding: Stereo-specific lipid-protein interactions are required to form HAMLET (human α -lactalbumin made lethal to tumor cells). *Protein Sci.* 2003;12:2805–14.
74. Polverino de Laureto P, Scaramella E, Frigo M, Wondrich FG, De Filippis V, Zamboni M, et al. Limited proteolysis of bovine α -lactalbumin: isolation and characterization of protein domains. *Protein Sci.* 1999;8:2290–303.
75. Svanborg C, Agerstam H, Aronson A, Bjerkvig R, Durringer C, Fischer W, et al. HAMLET kills tumor cells by an apoptosis-like mechanism—cellular, molecular, and therapeutic aspects. *Adv Cancer Res.* 2003;88:1–29.
76. Kohler C, Gogvadze V, Hakansson A, Svanborg C, Orrenius S, Zhivotovsky B. A folding variant of human α -lactalbumin induces mitochondrial permeability transition in isolated mitochondria. *Eur J Biochem.* 2001;268:186–91.
77. Kohler C, Hakansson A, Svanborg C, Orrenius S, Zhivotovsky B. Protease activation in apoptosis induced by MAL. *Exp Cell Res.* 1999;249:260–8.
78. Hallgren O, Gustafsson L, Irjala H, Selivanova G, Orrenius S, Svanborg C. HAMLET triggers apoptosis but tumor cell death is independent of caspases, Bcl-2 and p53. *Apoptosis.* 2006;11:221–33.
79. Codogno P, Meijer AJ. Autophagy and signaling: their role in cell survival and cell death. *Cell Death Differ.* 2005;12 Suppl 2:1509–18.
80. Baehrecke EH. Autophagy: dual roles in life and death? *Nat Rev Mol Cell Biol.* 2005;6:505–10.
81. Debnath J, Baehrecke EH, Kroemer G. Does autophagy contribute to cell death? *Autophagy.* 2005;1:66–74.
82. Durringer C, Hamiche A, Gustafsson L, Kimura H, Svanborg C. HAMLET interacts with histones and chromatin in tumor cell nuclei. *J Biol Chem.* 2003;278:42131–5.
83. Fischer W, Gustafsson L, Mossberg AK, Gronli J, Mork S, Bjerkvig R, et al. Human α -lactalbumin made lethal to tumor cells (HAMLET) kills human glioblastoma cells in brain xenografts by an apoptosis-like mechanism and prolongs survival. *Cancer Res.* 2004;64:2105–12.
84. Hakansson A, Andreasson J, Zhivotovsky B, Karpman D, Orrenius S, Svanborg C. Multimeric α -lactalbumin from human milk induces apoptosis through a direct effect on cell nuclei. *Exp Cell Res.* 1999;246:451–60.
85. Wenzel T, Baumeister W. Conformational constraints in protein degradation by the 20S proteasome. *Nat Struct Biol.* 1995;2:199–204.
86. Brest P, Gustafsson M, Mossberg AK, Gustafsson L, Durringer C, Hamiche A, et al. Histone deacetylase inhibitors promote the tumoricidal effect of HAMLET. *Cancer Res.* 2007;67:11327–34.
87. Gustafsson L, Leijonhufvud I, Aronsson A, Mossberg AK, Svanborg C. Treatment of skin papillomas with topical α -lactalbumin-oleic acid. *N Engl J Med.* 2004;350:2663–72.
88. Mossberg AK, Wullt B, Gustafsson L, Mansson W, Ljunggren E, Svanborg C. Bladder cancers respond to intravesical instillation of HAMLET (human α -lactalbumin made lethal to tumor cells). *Int J Cancer.* 2007;121:1352–9.
89. Makin OS, Atkins E, Sikorski P, Johansson J, Serpell LC. Molecular basis for amyloid fibril formation and stability. *Proc Natl Acad Sci U S A.* 2005;102:315–20.
90. Fernandez A, Berry RS. Proteins with H-bond packing defects are highly interactive with lipid bilayers: implications

- for amyloidogenesis. *Proc Natl Acad Sci U S A*. 2003; 100:2391–6.
91. Sparr E, Engel MF, Sakharov DV, Sprong M, Jacobs J, de Kruijff B, et al. Islet amyloid polypeptide-induced membrane leakage involves uptake of lipids by forming amyloid fibers. *FEBS Lett*. 2004;577:117–20.
 92. Zhao H, Jutila A, Nurminen T, Wickstrom SA, Keski-Oja J, Kinnunen PK. Binding of endostatin to phosphatidylserine-containing membranes and formation of amyloid-like fibers. *Biochemistry*. 2005;44:2857–63.
 93. Zhao H, Tuominen EK, Kinnunen PK. Formation of amyloid fibers triggered by phosphatidylserine-containing membranes. *Biochemistry*. 2004;43:10302–7.
 94. Utsugi T, Schroit AJ, Connor J, Bucana CD, Fidler IJ. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. *Cancer Res*. 1991;51:3062–6.
 95. Dobson CM. Protein folding and misfolding. *Nature*. 2003; 426:884–90.
 96. Fasano C, Campana V, Zurzolo C. Prions: protein only or something more? Overview of potential prion cofactors. *J Mol Neurosci*. 2006;29:195–214.
 97. Silveira JR, Raymond GJ, Hughson AG, Race RE, Sim VL, Hayes SF, et al. The most infectious prion protein particles. *Nature*. 2005;437:257–61.
 98. Gharibyan AL, Zamotin V, Yanamandra K, Moskaleva OS, Margulis BA, Kostanyan IA, et al. Lysozyme amyloid oligomers and fibrils induce cellular death via different apoptotic/necrotic pathways. *J Mol Biol*. 2007;365:1337–49.
 99. Goers J, Permyakov SE, Permyakov EA, Uversky VN, Fink AL. Conformational prerequisites for α -lactalbumin fibrillation. *Biochemistry*. 2002;41:12546–51.
 100. Yang F Jr, Zhang M, Zhou BR, Chen J, Liang Y. Oleic acid inhibits amyloid formation of the intermediate of α -lactalbumin at moderately acidic pH. *J Mol Biol*. 2006;362:821–34.
 101. Zhao H, Sood R, Jutila A, Bose S, Fimland G, Nissen-Meyer J, et al. Interaction of the antimicrobial peptide pheromone plantaricin A with model membranes: implications for a novel mechanism of action. *Biochim Biophys Acta*. 2006;1758:1461–74.
 102. Hakansson A, Svensson M, Mossberg AK, Sabharwal H, Linse S, Lazou I, et al. A folding variant of α -lactalbumin with bactericidal activity against *Streptococcus pneumoniae*. *Molecular microbiology*. 2000;35:589–600.
 103. Mok KH, Pettersson J, Orrenius S, Svanborg C. HAMLET, protein folding, and tumor cell death. *Biochem Biophys Res Commun*. 2007;354:1–7.
 104. Ren J, Stuart DI, Acharya KR. α -lactalbumin possesses a distinct zinc binding site. *J Biol Chem*. 1993;268:19292–8.
 105. Thompson J, Winter N, Terwey D, Bratt J, Banaszak L. The crystal structure of the liver fatty acid-binding protein. A complex with two bound oleates. *J Biol Chem*. 1997;272:7140–50.
 106. Koradi R, Billeter M, Wuthrich K. MOLMOL: a program for display and analysis of macromolecular structures. *J Mol Graph*. 1996;14:51–5, 29–32.